Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Not Yet Recruiting NCT07924059

Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Navepegritide and Lonapegsomatropin in Achondroplasia

Conditions: Achondroplasia

Sex: All

Ages: 2 Years – 17 Years

Healthy volunteers: No

Phase: PHASE3

Enrollment: 144

Sponsor: Ascendis Pharma A/S

Summary

This pivotal trial is being conducted to evaluate the efficacy, safety and tolerability of dual therapy with navepegritide and lonapegsomatropin administered as separate subcutaneous (SC) injections once weekly in children with achondroplasia (ACH) aged 2 to 17 years.

Eligibility Criteria

Inclusion Criteria: * 1\. Age 2 to \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07924059). StuddyBuddy aggregates publicly available trial information.